Mandate

Vinge advises Biotage in connection with RWK Bidco’s public tender

April 22, 2025 M&A

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.

Biotage is a global supplier and solutions partner to a wide range of customers within drug discovery and development and analytical testing. Headquartered in Sweden, Biotage operates globally serving over 80 countries. The company is listed on Nasdaq Stockholm. The offer values Biotage to approximately SEK 11,607 million based on the total number of ordinary shares in Biotage.

Vinge’s team mainly consists of Dain Hård Nevonen, Joel Magnusson, Benjamin Vafaeian, Lovisa Jonassen, Vilma Henricsson, David Olander and Emelie Schoning.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026